Automated Tests – Automated Home Cage-Based LightSpot Test
Assess anxiety in rodents
Key Research Model Applications of Automated Home Cage-Based LightSpot Test
The proprietary LightSpot Test is a one-night anxiety test that measures the rodent’s response to an anxiogenic stimulus in an automated home-cage. A light spot is switched on during the dark phase of the mouse, which induces anxiety-like behaviour. This can be observed as avoidance behaviour, such as hiding in the shelter compartment.
Mouse Behavioral Testing Made Simple.
Explore our extensive portfolio of validated and tailored behavioral and cognitive rodent tests designed to advance your research.
Automated Home Cage-Based LightSpot Test Sample Data
During the light spot test, a light is switched on during the dark phase of the mouse, inducing anxiety-like behaviour.
During the light spot test, a light is switched on during the dark phase of the mouse, inducing anxiety-like behaviour.
When a bright LightSpot was switched on during the dark phase in the PhenoTyper cage, control treated C57BL/6 mice spent less time outside of the shelter. This anxiety phenotype could be reversed with the golden-standard anxiolytic drug diazepam.
The People Behind Your Research
Thomas Vogels, PhD, In Vivo Neurology Study Director
Leads an expert team of scientists with vast experience in our Neurology models to help you choose the right model and guide your optimal study design. We provide the solution to accelerating your drug development.
Stay Curious: More Articles to Explore
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-1080x628.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com